Susana Teijeira

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3397516/publications.pdf

Version: 2024-02-01

471509 477307 40 874 17 29 citations h-index g-index papers 40 40 40 1161 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Description of the first Spanish case of Gerstmann–StrÃ ¤ ssler–Scheinker disease with A117V variant: clinical, histopathological and biochemical characterization. Journal of Neurology, 2022, , .	3.6	3
2	Clear cell clusters in the kidney: a rare finding that should not be misdiagnosed as renal cell carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 57-67.	2.8	1
3	Muscle weakness: Understanding the principles of myopathy and neuropathy in the critically ill patient and the management options. Clinical Nutrition, 2020, 39, 1331-1344.	5.0	9
4	Chimeric Peptide Species Contribute to Divergent Dipeptide Repeat Pathology in c9ALS/FTD and SCA36. Neuron, 2020, 107, 292-305.e6.	8.1	51
5	Fabry disease in the Spanish population: observational study with detection of 77 patients. Orphanet Journal of Rare Diseases, 2018, 13, 52.	2.7	20
6	Variable skeletal muscle involvement in VARS2 mitochondrial encephalomyopathy. Neuromuscular Disorders, 2016, 26, S178.	0.6	1
7	Spinal muscular atrophy with respiratory distress type 1 (SMARD1) Report of a Spanish case with extended clinicopathological follow-up., 2016, 35, 58-65.		7
8	LGMD1F: A morphological study. Neuromuscular Disorders, 2015, 25, S236.	0.6	0
9	Genotypic and phenotypic features of McArdle disease: insights from the Spanish national registry. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 322-328.	1.9	114
10	A novel MYH7 mutation links congenital fiber type disproportion and myosin storage myopathy. Neuromuscular Disorders, 2011, 21, 254-262.	0.6	47
11	P3.4 Spinal muscular atrophy with respiratory distress type 1 (SMARD-1). A clinico-pathological follow-up. Neuromuscular Disorders, 2011, 21, 683.	0.6	O
12	Molecular and clinical study of McArdle's disease in a cohort of 123 European patients. Identification of 20 novel mutations. Neuromuscular Disorders, 2011, 21, 817-823.	0.6	34
13	Chloroquine-induced myopathy. Lupus, 2011, 20, 773-774.	1.6	11
14	Shrinking lung syndrome caused by lupus myopathy. QJM - Monthly Journal of the Association of Physicians, 2011, 104, 259-262.	0.5	10
15	Characterisation of Lafora-like bodies and other polyglucosan bodies in two aged dogs with neurological disease. Veterinary Journal, 2010, 183, 222-225.	1.7	16
16	Chorionic villi ultrastructure in the prenatal diagnosis of glycogenosis type II. Journal of Inherited Metabolic Disease, 2010, 33, 105-111.	3.6	46
17	Histopathology of Skin in Fabry Disease. , 2010, , 275-292.		1
18	Molecular diagnosis of muscular dystrophies, focused on limb girdle muscular dystrophies. Expert Opinion on Medical Diagnostics, 2009, 3, 631-647.	1.6	0

#	Article	IF	CITATIONS
19	Permanent muscle weakness in M <scp>C</scp> Ardle disease. Muscle and Nerve, 2009, 40, 350-357.	2.2	59
20	Phenotypic variability in a Spanish family with a Caveolin-3 mutation. Journal of the Neurological Sciences, 2009, 276, 95-98.	0.6	20
21	Pathology and Diagnosis of Muscular Dystrophies. Advances in Experimental Medicine and Biology, 2009, 652, 1-11.	1.6	2
22	Myoadenylate deaminase deficiency: clinico-pathological and molecular study of a series of 27 Spanish cases., 2009, 28, 136-142.		26
23	G.P.16.05. McArdle disease. Molecular study of the myophosphorylase gene (PYGM) in a series of 120 patients. Neuromuscular Disorders, 2008, 18, 828.	0.6	0
24	Acute Necrotizing Encephalopathy of Childhood: Report of a Spanish Case. Pediatric Neurology, 2007, 37, 438-441.	2.1	23
25	M.P.2.11 Morphological studies in an eleven week-gestation foetus with glycogenosis II (Pompe) Tj ETQq1 1 0.784	1314 rgBT 0.6	/Overlock
26	G.P.13.16 Vacuolar myopathies. A morphological approach. Neuromuscular Disorders, 2007, 17, 853.	0.6	0
27	M.P.4.02 Permanent muscle weakness in McArdle disease. Neuromuscular Disorders, 2007, 17, 859-860.	0.6	1
28	Fabry disease: an ultrastructural comparative study of skin in hemizygous and heterozygous patients. Acta Neuropathologica, 2006, 111, 178-185.	7.7	27
29	Autosomal dominant congenital fibre type disproportion: a clinicopathological and imaging study of a large family. Brain, 2005, 128, 1716-1727.	7.6	18
30	Miliary brain metastases presenting as rapidly progressive dementia. Neuropathology, 2005, 25, 153-158.	1.2	21
31	A New Rare Mutation (691delCC/insAAA) in Exon 17 of the PYGM Gene Causing McArdle Disease. Archives of Neurology, 2004, 61, 1108-10.	4.5	11
32	Oxidation of methionine residues in the prion protein by hydrogen peroxide. Archives of Biochemistry and Biophysics, 2004, 432, 188-195.	3.0	82
33	Beta-sarcoglycanopathy (LGMD 2E) in a Spanish family. Acta Myologica, 2004, 23, 159-62.	1.5	3
34	Unusual clinical findings and Complex III deficiency in a family with myotonic dystrophy. Journal of the Neurological Sciences, 2003, 208, 87-91.	0.6	7
35	Identification of six novel mutations in the acid alpha-glucosidase gene in three Spanish patients with infantile onset glycogen storage disease type II (Pompe disease). Neuromuscular Disorders, 2002, 12, 159-166.	0.6	27
36	Molecular heterogeneity of myophosphorylase deficiency (Mcardle's disease): A genotype-phenotype correlation study. Annals of Neurology, 2001, 50, 574-581.	5.3	86

Susana Teijeira

#	Article	IF	CITATION
37	A Novel Missense Mutation (W797R) in the Myophosphorylase Gene in Spanish Patients With McArdle Disease. Archives of Neurology, 2000, 57, 217.	4.5	19
38	Evaluation of heart involvement in gamma-sarcoglycanopathy (LGMD2C). A study of ten patients. Neuromuscular Disorders, 2000, 10, 560-566.	0.6	40
39	Adult glycogenosis II with paracrystalline mitochondrial inclusions and Hirano bodies in skeletal muscle. Neuromuscular Disorders, 1999, 9, 136-143.	0.6	24
40	Subsarcolemmal expression of utrophin in neuromuscular disorders: an immunohistochemical study of 80 cases. Acta Neuropathologica, 1998, 96, 481-486.	7.7	7